Arikayce

28
Aug

Arikayce

August 28, 2018
Arikayce for Nontuberculous Mycobacteria The purpose of this randomized, placebo-controlled study is to evaluate the efficacy, safety and tolerability of 84 days of daily dosing of 590 mg of liposomal amikacin for inhalation (LAI) versus placebo in patients with recalcitrant Mycobacterium avium complex lung disease. The primary outcome measure is proportion of subjects with culture...
Read More
28
Aug

Clofazimine

August 28, 2018
Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex The purpose of this study is to evaluate the clinical effectiveness and safety of clofazimine when used to treat Mycobacteria avium complex (MAC) lung disease. Clofazimine has been used for many years off-label against other Mycobacteria, including Mycobacteria avium complex (MAC) lung disease, an increasingly prevalent...
Read More
28
Aug

Lung Microbiome

August 28, 2018
Evaluation of the Lung Microbiome in NTM Bronchiectasis A biomarker cohort study design is proposed to study whether specific airway microbiota alterations are associated with pulmonary Non-tuberculous mycobacteria (NTM) disease. In a cohort of 200 subjects suspected of having pulmonary NTM disease, the investigators will evaluate the airway microbiome using an aliquot of the induced...
Read More
28
Aug
Study of Mycobacterial Infections This study will examine the symptoms, course of disease and treatment of non-tuberculous mycobacterial (NTM) infections, as well as the genetics involved in these infections. Patients with NTM have recurrent lung infections and sometimes infections of the skin and other organs as well. They may also have curvature of the spine,...
Read More

WHAT IS NTM?

“NTM” is short for Nontuberculous Mycobacteria. NTM disease is a serious chronic lung illness.

Learn More